

September 26, 2024

Contents

Clinical Profile Documentation	2
Problem Groups	2
Additions	2
Problems.....	2
Additions.....	2
Lab Analytes & Panels	3
Additions.....	3
Lab Analytes	3
Panels.....	3
Medications.....	5
Additions.....	5
Updates	5
Regimen Library.....	7
Bispecific Antibody Monitoring.....	7
Additions.....	7
Updates	8
Renames	8
Removals	9
Billing & HCPCS Codes	10
Updates	10
ICD-10-CM.....	11
Updates	11
NDC – HCPCS Crosswalk	11
Additions.....	11

Clinical Profile Documentation

Problem Groups

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

Line of Therapy has been updated for **Small cell, lung cancer** with the following documentation points:

- **Consolidation (limited stage)** is now available
- **Maintenance (extensive stage)** is now available
- **Maintenance** is no longer available

Problems

Additions

New items are available for documentation in **Problems** and appear in the **Charge Capture Report (CCR)**. Additional ICD-10 codes may be displayed to present the surrounding nodes.

To appropriately align ICD-10 codes within problems, “I10 – Essential (primary) hypertension” was removed from the following problems:

- Brachydactyly syndrome type E (disorder)
- Chronic hypertension in obstetric context (disorder)
- Dementia due to hemorrhagic cerebral infarction due to hypertension (disorder)
- Dementia due to hypertensive encephalopathy (disorder)
- Dementia due to metabolic abnormality (disorder)
- Essential hypertension in obstetric context (disorder)
- Good hypertension control (finding)
- Headache due to arterial hypertension (finding)
- Hemorrhagic cerebral infarction (disorder)
- Hemorrhagic cerebral infarction due to hypertension (disorder)
- Hemorrhagic infarction (disorder)
- Hereditary dysplasia of blood vessel (disorder)
- Hypertension in the obstetric context (disorder)
- Hypertension monitoring offer default (finding)
- Hypertension monitoring status (finding)
- Hypertensive optic neuropathy (disorder)

- Hypertensive treatment changed (situation)
- Increased blood pressure (finding)
- Progressive arterial occlusive disease, hypertension, heart defect, bone fragility, brachysyndactyly syndrome (disorder)
- Transient hypertension (disorder)
- Ulcer of lower leg due to arterial hypertension (disorder)
- Ulcer of lower limb due to arterial hypertension (disorder)

Lab Analytes & Panels

Additions

Lab Analytes

- Amyloidosis DNA sequence gene analyzed
- Amyloidosis DNA sequence test description
- Brushite saturation
- Calcium/Kg body weight, mg/24hr/kg
- Calculus weight, mg
- Creatinine/Kg body weight, mg/24hr/kg
- Cystine capacity, mg/L
- Cystine saturation
- Cystine, quant, urine, mg/24hr
- Dako PD-L1 IHC 22C3
- Ehrlichia antibody panel comment
- Ganglioside (GQ1B) ab (IgG) panel
- Ganglioside (GQ1B) ab IgG titer
- Human influenza A virus subtype H1pdm09
- Infliximab interpretation
- Litholink 24hr cystine profile comment
- MyoMarker panel 3 plus
- pH, 24hr, urine
- Protein catabolic rate, g/kg/24hr
- T-cell receptor gamma tube A, BP
- T-cell receptor gamma tube B, BP
- Thrombin antithrombin complex AG, ug/L
- Urine volume (preserved), mL/24hr

Panels

MuSK antibody panel

- MuSK antibody, nmol/L

Platelet antibody screen panel

- Platelet antibody screen overall result
- Platelet antibody screen interpretation
- GPIIb/IIIa (cell-1)
- GPIIb/IIIa (cell-2)
- GPIa/IIa (cell-1)
- GPIa/IIa (cell-2)
- GPIb/IX
- GPIV
- HLA class I antibody
- Platelet antibody screen reason for request
- IVIG in last month

Oxalate, blood panel

- Oxalate, blood, umol/L

Cystatin C with estimated GFR panel

- EGFR by Cystatin C, mL/min/BSA
- Cystatin C

Bone marrow AFB culture panel

- Bone marrow AFB culture

Non gyn cytology w/reflex panel

- Pathology/Cytology clinical history
- Pathology/Cytology source of specimen
- Pathology/Cytology gross description
- Pathology/Cytology specimen adequacy
- Pathology/Cytology diagnosis
- Pathology/Cytology note
- Pathology/Cytology screened by
- Pathology/Cytology reviewed by

FISH, MDS/Myeloid panel

- FISH, MDS/Myeloid result

Medications

Additions

- 225Ac-DOTATATE invest (RYZ101 invest IV)
- ALT2618 invest Oral
- AMT-116 invest IV
- BGB-11417 invest Oral
- DM005 invest IV
- Fianlimab-Cemiplimab invest (REGN3767-REGN2810 invest IV)
- KQB198 invest Oral
- LOXO-435 invest Oral
- Miracle Mouthwash (Diphenhydramine-Dexamethasone-Nystatin)
- MK-1026 invest Oral
- Nemtabrutinib invest (MK-1026 invest Oral)
- REGN3767-REGN2810 invest IV
- RP1-104 invest Intratumoral
- RYZ101 invest IV
- Sonrotoclax invest (BGB-11417 invest Oral)
- Vusolimogene Oderparepvec invest (RP1-104 invest Intratumoral)

Updates

Medication	Update
ATRN-119 invest Oral	New form available: 100 mg capsule
BBO-10203 invest Oral	New form available: 150 mg tablet
Bevacizumab IV	Updated drug instructions : Dilute with NS to a total volume of 100 ml. Administer over 30 minutes. NOTE: This is Avastin.
Bevacizumab-adcd IV	Updated drug instructions : Dilute with NS to a total volume of 100 ml. Administer over 30 minutes. NOTE: This is Vegzelma.
Bevacizumab-awwb IV	Updated drug instructions : Dilute with NS to a total volume of 100 ml. Administer over 30 minutes. NOTE: This is Mvasi.
Bevacizumab-bvzr IV	Updated drug instructions : Dilute with NS to a total volume of 100 ml. Administer over 30 minutes. NOTE: This is Zirabev.
Ferric Derisomaltose IV	Added maximum single dose : 1,000 mg
Hyaluronate Sodium, Stabilized Intra-Articular 60 mg/3 mL	Brand name linked to Generic name: Durolane
Ianalumab (VAY736) invest IV	New quick sig available: 0 mL intravenously once
MGA012 invest IV	Update drug name : Retifanlimab invest IV
SPYK04 invest Oral	New form available: 0.2 mg capsule New quick sig available: 0.2 mg orally daily; Take every 24 hours with water on an empty stomach (no food or

Medication	Update
	drink other than water for at least 2 hours prior to dose and at least 1 hour after dose). Take in clinic when instructed. Store in refrigerator.
tovorafenib Suspension via feeding tube	<p>New maximum single dose: 600 mg via feeding tube New drug instructions: Take with or without food New quick sigs available:</p> <ul style="list-style-type: none"> • tovorafenib Suspension 0 mL via feeding tube As Directed • tovorafenib Suspension 0 mL via feeding tube every 7 days; per package directions • tovorafenib Suspension 6 mL via feeding tube every week; for BSA 0.36-0.42 m² • tovorafenib Suspension 7 mL via feeding tube every week; for BSA 0.43-0.48 m² • tovorafenib Suspension 8 mL via feeding tube every week; for BSA 0.49-0.54 m² • tovorafenib Suspension 9 mL via feeding tube every week; for BSA 0.55-0.63 m² • tovorafenib Suspension 11 mL via feeding tube every week; for BSA 0.64-0.77 m² • tovorafenib Suspension 12 mL via feeding tube every week; for BSA 0.78-0.83 m² • tovorafenib Suspension 14 mL via feeding tube every week; for BSA 0.84-0.89 m² • tovorafenib Suspension 15 mL via feeding tube every week; for BSA 0.90-1.05 m² • tovorafenib Suspension 18 mL via feeding tube every week; for BSA 1.06-1.25 m² • tovorafenib Suspension 21 mL via feeding tube every week; for BSA 1.26-1.39 m² • tovorafenib Suspension 24 mL via feeding tube every week; for BSA greater than or equal to 1.4 m²
Vorasicenib Oral	New drug instructions : Take with or without food. New quick sigs available: 40 mg orally As Directed
Ziftomenib invest (KO-539 invest Oral)	New quick sigs available: <ul style="list-style-type: none"> • 0 mg orally daily; on days 1-28 of each 28 day cycle for up to 2 years. Should be taken at least 1 hour before or 2 hours after a meal with 8 oz of water. • 0 mg/m² orally daily • 0 mg/kg orally daily

Regimen Library

Bispecific Antibody Monitoring

To promote best practices and increase patient safety, **Bispecific Antibody Monitoring** communication orders have been added to **Multiple Myeloma** bispecific antibody regimen templates.

The Collaborative Care Committee has voted in favor of the addition of the communication orders with contingencies to include updated formatting highlighting drug-specific recommendations.

These updates will be implemented in a future content release.

Additions

Regimen Name	Diagnosis
Daratumumab IV + Carfilzomib D1,2,8,9,15,16 fb D1,2,15,16 + Pomalidomide D1-21 + Dexamethasone Q28D	Multiple Myeloma (MM)
Daratumumab IV + Carfilzomib D1,2,8,9,15,16 fb D1,2,15,16 + Pomalidomide D1-21 + Dexamethasone Q28D (C1 Split Dosing)	Multiple Myeloma (MM)
Daratumumab SQ + Carfilzomib D1,2,8,9,15,16 fb D1,2,15,16 + Pomalidomide D1-21 + Dexamethasone Q28D	Multiple Myeloma (MM)
Durvalumab + Gemcitabine D1,8 + Cisplatin Q21D (NSCLC)	Lung Cancer, Non-small Cell (NSCLC)
Durvalumab + Paclitaxel + Carboplatin Q21D (NSCLC)	Lung Cancer, Non-small Cell (NSCLC)
Durvalumab + Pemetrexed + Carboplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)
Durvalumab + Pemetrexed + Cisplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)
Durvalumab Q28D (Flat Dose) (Perioperative NSCLC)	Lung Cancer, Non-small Cell (NSCLC)
Lazertinib + Amivantamab-vmjw (weight greater than or equal to 80 kg) D1,15 Q28D	Lung Cancer, Non-small Cell (NSCLC)
Lazertinib + Amivantamab-vmjw (weight less than 80 kg) D1,15 Q28D	Lung Cancer, Non-small Cell (NSCLC)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- All Problems
- Arthritis, Rheumatoid
- Bile Duct Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gallbladder Cancer
- Gastric Cancer
- Head and Neck Cancer (Parent)
- Hepatocellular Carcinoma (HCC)
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Skin
- Melanoma, Uvea, Ciliary Body/Choroid
- Melanoma, Uvea, Iris
- Multiple Myeloma (MM)
- Myelodysplastic Syndrome (MDS)
- Ovarian and Primary Peritoneal Cancer
- Pancreatic Cancer
- Paroxysmal Nocturnal Hemoglobinuria
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Renal Pelvis and Ureter Cancer
- Sarcoma, Bone (Parent)
- Sarcoma, Soft Tissue (Parent)
- Solid Tumors (Parent) (including Solid Other/HL)
- Urethral Cancer
- Uterine Cancer (Parent)

Renames

Previous Name	New Name
Ado-trastuzumab emtansine Q21D	Ado-Trastuzumab Emtansine (Kadcyla) Q21D
Ado-Trastuzumab Emtansine Q21D (Adjuvant Breast Residual Disease)	Ado-Trastuzumab Emtansine (Kadcyla) Q21D (Adjuvant Breast Residual Disease)
Ado-Trastuzumab emtansine Q21D (Initial Adjuvant Breast)	Ado-Trastuzumab Emtansine (Kadcyla) Q21D (Initial Adjuvant Breast)
Fam-Trastuzumab Deruxtecan-nxki (5.4 mg/kg) Q21D	Fam-Trastuzumab Deruxtecan-nxki (Enhertu) (5.4 mg/kg) Q21D
Fam-Trastuzumab Deruxtecan-nxki (6.4 mg/kg) Q21D.	Fam-Trastuzumab Deruxtecan-nxki (Enhertu) (6.4 mg/kg) Q21D
Mosunetuzumab-axgb D1,8,15 fb D1 Q21D	Mosunetuzumab-axgb (Lunsumio) D1,8,15 fb D1 Q21D

Previous Name	New Name
Obinutuzumab D1 fb Glofitamab-gxbm D8,15 fb D1 Q21D	Obinutuzumab D1 fb Glofitamab-gxbm (Columvi) D8,15 fb D1 Q21D
Tarlatamab-dlle IV D1,8,15 fb D1,15 Q28D	Tarlatamab-dlle (Imdelltra) D1,8,15 fb D1,15 Q28D
Tebentafusp-tebn D1,8,15 Q21D (Initial)	Tebentafusp-tebn (Kimmtrak) D1,8,15 Q21D (Initial)
Tebentafusp-tebn D1,8,15,22 Q28D (Maintenance)	Tebentafusp-tebn (Kimmtrak) D1,8,15,22 Q28D (Maintenance)
Teclistamab-cqyv SQ D1,4,7 (Initial)	Teclistamab-cqyv (Tecvayli) SQ D1,4,7 (Initial)
Teclistamab-cqyv SQ D1,8,15,22 fb D1,15 Q28D (Maintenance)	Teclistamab-cqyv (Tecvayli) SQ D1,8,15,22 fb D1,15 Q28D (Maintenance)
Teclistamab-cqyv SQ Option D1,3,5 (Initial)	Teclistamab-cqyv (Tecvayli) SQ Option D1,3,5 (Initial)

Removals

Regimen Name	Diagnosis
Daratumumab SQ + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 1 of 2: Induction)	Multiple Myeloma (MM)
Daratumumab SQ + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 2 of 2: Post-transplant Consolidation)	Multiple Myeloma (MM)
Daratumumab IV + Ixazomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D	Multiple Myeloma (MM)
Daratumumab SQ + Ixazomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D	Multiple Myeloma (MM)
Daratumumab IV + Bortezomib + Melphalan PO + Prednisone Q42D (Part 1 of 2)	Multiple Myeloma (MM)
Daratumumab IV + Bortezomib + Melphalan PO + Prednisone Q42D (Part 1 of 2: C1 Split Dosing)	Multiple Myeloma (MM)
Daratumumab IV + Bortezomib + Melphalan PO + Prednisone Q28D (Part 2 of 2: Daratumumab IV only)	Multiple Myeloma (MM)
Daratumumab SQ + Bortezomib + Melphalan PO + Prednisone Q42D (Part 1 of 2)	Multiple Myeloma (MM)
Daratumumab SQ + Bortezomib + Melphalan PO + Prednisone Q28D (Part 2 of 2: Daratumumab SQ only)	Multiple Myeloma (MM)

Billing & HCPCS Codes

Updates

The October 2024 updates include new HCPCS Level II codes to separately identify products approved under the 505(b)(2) New Drug Application (NDA) or the Biologics License Applications (BLA) pathways after October 2003, and not rated as therapeutically equivalent to a reference listed product in an existing code.

- The complete HCPCS Application Summaries and Coding Recommendations can be found [here](#).
- The complete list of October 2024 [HCPCS quarterly updates](#), can be found on CMS's website.

For medications listed below that include a brand name, please refer to the NDC – HCPCS crosswalk table within the release notes for specific dispensable/NDC association.

Medication	HCPCS Codes
Acetaminophen and Ibuprofen Injection	J0138 Per 1000 mg
Capecitabine Oral	J8522 per 50 mg
Dexamethasone Oral	J8541 per 0.25 mg
Dexamethasone Oral (Hemady)	J8541 per 0.25 mg
Hydromorphone Injection	J1171 per 0.1 mg
Influenza virus vaccine IM Tri-Split (6 months & older) Cell derived	90661 per 0.5 mL
Lidocaine (Baxter)	J2002 per 1 mg
Lidocaine (Braun)	J2002 per 1 mg
Lidocaine (Fresenius Kabi)	J2003 per 1 mg
Lidocaine (Hospira)	J2003 per 1 mg
Lidocaine (International Medication Systems)	J2003 per 1 mg
Midazolam	J2252 per 1 mg
Nemolizumab-ilto Subcutaneous Pen Injector	J3590 per 30 mg
Palonosetron IV	J2468 per 0.25 mg
Palopegteriparatide Subcutaneous Pen Injector	J3590 per 168 mcg
Pneumococcal 21-val conj-dip crm (PF) IM	90684 per 0.5 mL
Rocuronium IV	J3490 per 1 mg

Medication	HCPCS Codes
Tislelizumab-jsgr Injection	J9329 per 1 mg
Tocilizumab-aazg IV	Q5135 per 1 mg
Tocilizumab-aazg Subcutaneous	Q5135 per 1 mg
Vasopressin Continuous Intra-Arterial Infusion	J2601 per 1 unit
Vasopressin IV	J2601 per 1 unit

ICD-10-CM

Updates

The upcoming FY25 CMS changes to the ICD-10-CM coding guidelines and code set effective on Oct. 1, 2024, have been released. The complete code set changes can be found [here](#).

NDC – HCPCS Crosswalk

Additions

Medication (Brand)	HCPCS Code	NDC
Bendamustine (Treanda)	J9033 per 1 mg	<ul style="list-style-type: none"> 10019007901 60505622800
Dexamethasone (Hemady)	J8541 per 0.25 mg	<ul style="list-style-type: none"> 72893001524 72893001506 82111095501 82111095502
Lidocaine (Baxter)	J2002 per 1 mg	<ul style="list-style-type: none"> 00338040903 00338041102
Lidocaine (Braun)	J2002 per 1 mg	<ul style="list-style-type: none"> 00264959410 00264959420 00264959820
Lidocaine (Fresenius Kabi)	J2003 per 1 mg	<ul style="list-style-type: none"> 6332320801 6332320805 63323049889

Medication (Brand)	HCPCS Code	NDC
Lidocaine (Hospira)	J2003 per 1 mg	<ul style="list-style-type: none"> • 00409132305 • 00409132315 • 00409490311 • 00409490334 • 00409490411 • 00409490434 • 00409913705 • 00409913711
Lidocaine (International Medication Systems)	J2003 per 1 mg	<ul style="list-style-type: none"> • 76329339001
Midazolam	J2252 per 1 mg	<ul style="list-style-type: none"> • 51754213101 • 51754213104
Palonosetron (Avyxa)	J2468 per 0.25 mg	<ul style="list-style-type: none"> • 83831010501
Vasopressin (Baxter)	J2601 per 1 unit	<ul style="list-style-type: none"> • 00338964012 • 00338964712